MA Transfer Date definition

MA Transfer Date means, in relation to the Territory, the date upon which the relevant Regulatory Authority approves and notifies the Marketing Authorization naming the Purchaser or the Purchaser’s Affiliate or designate as the marketing authorization holder.
MA Transfer Date has the meaning set forth in the Asset Purchase Agreement.
MA Transfer Date means, in relation to each country of the Territory, the date upon which the relevant Regulatory Authority approves and notifies the Marketing Authorization, naming the Purchaser or the Purchaser’s Affiliate or designate as the marketing authorization holder.

Examples of MA Transfer Date in a sentence

  • Purchaser shall immediately notify Novartis in writing regarding the MA Transfer Date.

  • However, Novartis shall grant Purchaser the permission, subject to local laws and regulations, to sell off Product sourced from Novartis prior to or after the MA Transfer Date.

  • Purchaser’s right to use the Novartis names and marks, the Novartis logo including the light blue triangle and other trade dress elements featured on the Product and Product packaging, leaflets and marketing material in the Territory shall expire upon the MA Transfer Date.

  • Furthermore, Novartis is not responsible for conducting any studies, including clinical and stability studies, concerning the Drug Substances and/or the Products, which may be requested by the Regulatory Authority or any Governmental Authority after the Closing Date, regardless of whether the MA Transfer Date has occurred or not.

  • No later than the MA Transfer Date Novartis shall, or shall ensure that its Affiliates shall take the necessary action to formalize the effective assignment of its or their rights and obligations related to the Products under those Third Party Agreements listed in PARTS A of the Annex 5 and that can be assigned partially to the Purchaser without the consent of the respective Third Party.

  • Prior to the MA Transfer Date, and in time to ensure that all regulatory requirements are met, the Parties shall enter into a Pharmacovigilance Agreement for one of the Products, namely Visken, which will be attached hereto as Annex 7 after execution.

  • INDEMNIFICATION: I, the PARTICIPANT, and/or I as a PARENT/GUARDIAN of a MINOR PARTICIPANT, agree to hold harmless, defend, and indemnify ACTION CITY and the Protected Parties (that is, defend and pay any judgment and costs, including investigation costs, attorney’s fees and related expenses) from any and all claims of the Releasing Parties arising from my injury or loss due to the participation at ACTION CITY arising from the ordinary negligence of ACTION CITY or Protected Parties.

  • Subject to the conditions set forth in the Part C Agreement, Novartis shall remove/delist the Products from the scope of the Part C Agreement following the Closing Date but no earlier than the MA Transfer Date with respect to each of the Products.

  • In the event that such consent is not obtained, then Novartis and the Purchaser shall consider alternative solution because Novartis or its Affiliates remains as the contracting party under such Tenders related to the Products for the duration of such Tenders and until the MA Transfer Date.

  • The Purchaser shall use commercially reasonable efforts to secure the listing of each of the Products with such Third Party under the name of the Purchaser following the Closing Date, with each listing with respect to the Products to take effect from the MA Transfer Date.


More Definitions of MA Transfer Date

MA Transfer Date has the meaning given in Clause 13.8;
MA Transfer Date means, in relation to each country of the Territory, the date upon which the relevant Regulatory Authority approves and notifies the Marketing Authorization, naming the Purchaser or the Purchaser’s Affiliate or designate as the marketing authorization holder. “Medical Information” means any medical or clinical information related to the Product owned by and used by Novartis, in the form currently maintained in the Books and Records of Novartis and/or its Affiliates, at the Closing Date, including clinical and technical matters, such as therapeutic uses for the approved indications, drug‑disease information, and other product characteristics. “Milestone Payments” shall have the meaning set forth in Clause 9.2. “NAG” shall have the meaning set forth in the Preamble. “Non-transferred Marketing Authorizations” shall have the meaning set forth in Clause 5.1(b). “Novartis” shall have the meaning set forth in the Preamble. “NPAG” shall have the meaning set forth in the Preamble. “Omitted Transferred Asset” shall have the meaning set forth in Clause 5.3. “Party” and “Parties” shall have the meanings set forth in the Preamble. “PDL” means PDL BioPharma, Inc., a Delaware corporation. “Permits” means all licenses, permits, approvals or authorizations of any Governmental Entity with respect to manufacturing of the Drug Substance or the Product. 7 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions “Permitted Encumbrance” means (i) liens for taxes or governmental assessments not yet due and payable or for taxes or governmental assessments being contested in good faith through appropriate proceedings for which adequate accruals or reserves have been established in the audited financial statements of Novartis and (ii) mechanics’, carriers’, workers’, repairers’ and similar statutory liens arising or incurred in the ordinary course of business consistent with past practice that are not, individually or in the aggregate, material to the Business of the Transferred Assets, for amounts that are not delinquent, for which adequate accruals or reserves have been established on the audited financial statements of Novartis. “Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity. “Phase 1 Period” means the period, on a country‑by‑cou...